Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
24 Exenatide FDA product information (2023)
Several companies have GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual agonists in phase 1 studies, including SCO-094 (Scohia Pharma), VK2735 (Viking Therapeutics) and CT-388 (Carmot Therapeutics)
External resources Network Meta-Analysis: Tirzepatide vs Liraglutide in Type 2 Diabetes (PMC) Comparative Effectiveness of GLP-1 Medications (Frontiers in Pharmacology) For researchers committed to making data-driven decisions about their protocols, SeekPeptides provides comprehensive comparison tools, evidence-based guides, and a community of experienced users who have navigated these exact questions
For all trials, subjects had a minimum HbA 1c of 7.0%, and there were no restrictions on body weight or body mass index (BMI)
We tested 50 and 25% (w/v) ZIL aq
US$ 25.28
US$ 29.44
US$ 28.30
US$ 26.86
US$ 29.29
US$ 24.96
US$ 21.54
US$ 22.27
